Scroll Top

Closing the loop with SGLT2 inhibitors for CKD management




Broadcast Friday 20 May, Virtual Symposium, ERA 2022

With emerging data and new treatment options available, a clear, multidisciplinary approach to treating chronic kidney disease (CKD) patients is required. Nephrologists have an important role to play in both supporting colleagues to identify patients with CKD and ensuring patients are given appropriate treatment to optimize renal protection and slow disease progression.

Watch our Chair Kieran McCafferty (UK) and speakers Adeera Levin (Canada) and Beatriz Fernández-Fernández (Spain) as they discuss the importance of this role and provide practical advice on identifying patients most likely to benefit from SGLT2 inhibitors.

You can jump to the specific presentations, including the Q&A session, using the chapter selector in the video player.

Your experience is important as it helps us design the best learning activities for you.

Please take a moment to feedback here.

Note you must fill out an evaluation form if you would like to claim for credits.

Learning objectives

After this activity you will be able to:

1. Describe the importance of a clear approach to optimize care for CKD patients
2. Identify CKD patients who would most benefit from SGLT2 inhibitor therapy
3. Debate the nephrologist’s role in the MDT – elevating the importance of addressing CKD and leading synergized and optimized patient care


Welcome & introduction Kieran McCafferty (Chair)
Why & how should we optimize care for patients with CKD? Adeera Levin
In which patients should we use SGLT2 inhibitors? Beatriz Fernández-Fernández
Faculty Q&A All

Our faculty

Kieran McCafferty (Chair)

Consultant Nephrologist, Barts Health NHS Trust, UK

Kieran McCafferty is a Consultant Nephrologist at Barts Health National Health Service Trust and Senior Lecturer at Queen Mary University London, UK. His main clinical interests are diabetic kidney disease and haemodialysis. His basic science research interests are in the field of uraemic cardiovascular disease and cardiovascular protection. However, he spends most of his research time developing and delivering clinical trials at both a local and national level. He has a passion for clinical trial delivery having led over 40 National Institute for Health Research (NIHR) clinical trials in the last 5 years. He is the renal clinical trials lead for Barts Health and the Diabetic Kidney disease Centre and is the divisional director of research for specialist medicine at Barts Health and the deputy clinical director of research and development in the trust.

To help deliver patient-focused research across the UK, Dr McCafferty is the vice chair of the City and East London Ethics committee as well as the North Thames NIHR renal lead and deputy NIHR renal lead.


  • Grants research support from AstraZeneca
  • Honoraria/consultation fees from AstraZeneca, Bayer, Napp, Pharmacosmos, Oncacare
Adeera Levin

Head of the Division of Nephrology, University of British Columbia, Canada

Adeera Levin is a Professor of Medicine, Head of the Division of Nephrology at the University of British Columbia, and Consultant Nephrologist at Providence Health Care/St Paul’s Hospital, in Vancouver, Canada.

She is the Executive Director of the BC Renal Agency, which oversees kidney services in British Columbia. Her major research areas of interest include CKD progression and variability, non-traditional risk factors for cardiovascular disease in CKD patients, health systems redesign, implementation science, and models of care. She has received numerous teaching and research awards from local and national groups, including the National Kidney Foundation’s International Distinguished Medal for 2015 and the highest civilian honour, The Order of Canada in 2015.

Dr Levin is the past President of the International Society of Nephrology (ISN; between 2015 and 2017), and has previously served as Research Committee Chair, and is now Deputy Chair, of ISN Advancing Clinical Trials. She serves on numerous editorial boards and reviews for major kidney and medicine journals, and she is the Principal Investigator on the largest pan-Canadian patient-oriented network grant, CAN SOLVIE CKD.


AstraZeneca, Bayer, Boehringer Ingelheim, Otsuka Pharmaceutical

Beatriz Fernández-Fernández

Staff Nephrologist, Fundación Jiménez Díaz University Hospital Health Research Institute, Spain

Beatriz Fernández-Fernández is a Staff Nephrologist at the Fundación Jiménez Díaz University Hospital Health Research Institute (IIS-FJD), Director of the diabetic kidney disease clinic, and Assistant Professor in Medicine in the Universidad Autónoma in Madrid, Spain. She is an early career researcher, having obtained her PhD in 2017. Expertscape already identifies her as one of the top 40 European and top 4 Spanish researchers in the diabetic kidney disease field, according to her publication track record of the most recent 10 years. She is a Scientist-Physician and Researcher in the Nephrology, Vascular Pathology, Hypertension and Diabetes group at IIS-FJD. She is the former secretary of JovSEN (young platform of the Spanish Society of Nephrology), and current board member of both EURECAm (European Renal and cardiovascular medicine) and GEENDIAB (Spanish Diabetic Nephropathy Group).

She is mainly interested in diabetic kidney diseases and their implications in special populations, as well as gender differences in both CKD and diabetic kidney diseases. She is Principal Investigator for the Instituto de Salud Carlos III research project “Gender differences in the evolution and results of treated diabetic kidney disease” and has been an investigator for EU projects, for example as EC PRIORITY Coordinator.


  • Grants research support from Instituto de Salud Carlos III RICORS program to RICORS2040 (RD21/0005/0001), FEDER funds, Instituto de Salud Carlos III P120/00744
  • Honoraria/consultation fees from AstraZeneca, Boehringer-Lilly, Bayer, Novo-Nordisk, Mundipharma


Expiration date of accreditation: 20 May 2023
Closing the loop with SGLT2 inhibitors for CKD management, Paris, France, 20/05/2022-20/05/2022 has been granted 1 European CME credits (ECMEC®s) by the European Accreditation Council for Continuing Medical Education (EACCME®).

To claim your credits and collect your certificate please fill out the feedback form. Scan the QR code at the congress or on the program schedule or follow the link at the end of the evaluation form.

The Closing the loop with SGLT2 inhibitors for CKD management, Paris, France, 20/05/2022-20/05/2022 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 1 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Educational grant

AstraZeneca has provided an educational grant towards this independent program.

healthcare professionals completing our programs
educational programs launched
countries receiving live education


Rebecca Cox

Principal Medical Education Writer

Related Programs |view all programs